Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/12688
Title: A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production.
Austin Authors: Nachbur, Ueli;Stafford, Che A;Bankovacki, Aleksandra;Zhan, Yifan;Lindqvist, Lisa M;Fiil, Berthe K;Khakham, Yelena;Ko, Hyun-Ja;Sandow, Jarrod J;Falk, Hendrik;Holien, Jessica K;Chau, Diep;Hildebrand, Joanne;Vince, James E;Sharp, Phillip P;Webb, Andrew I;Jackman, Katherine A;Mühlen, Sabrina;Kennedy, Catherine L;Lowes, Kym N;Murphy, James M;Gyrd-Hansen, Mads;Parker, Michael W;Hartland, Elizabeth L;Lew, Andrew M;Huang, David C S;Lessene, Guillaume;Silke, John
Affiliation: The Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, Austin Campus, 245 Burgundy Street, Heidelberg, Victoria 3084, Australia
ACRF Rational Drug Discovery Centre, St Vincent's Institute of Medical Research, 9 Princes Street, Fitzroy, Victoria 3065, Australia
Department of Microbiology and Immunology, University of Melbourne, Victoria 3010, Australia
Department of Disease Biology, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark
Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford OX3 7DQ, UK
Cancer Therapeutics CRC, Bundoora, Victoria 3083, Australia
The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Victoria 3052, Australia
ACRF Rational Drug Discovery Centre, St Vincent's Institute of Medical Research, 9 Princes Street, Fitzroy, Victoria 3065, Australia
Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Victoria 3010, Australia
Department of Medical Biology, University of Melbourne, Melbourne, Victoria 3010, Australia
Issue Date: 17-Mar-2015
Publication information: Nature Communications 2015; 6(): 6442
Abstract: Intracellular nucleotide binding and oligomerization domain (NOD) receptors recognize antigens including bacterial peptidoglycans and initiate immune responses by triggering the production of pro-inflammatory cytokines through activating NF-κB and MAP kinases. Receptor interacting protein kinase 2 (RIPK2) is critical for NOD-mediated NF-κB activation and cytokine production. Here we develop and characterize a selective RIPK2 kinase inhibitor, WEHI-345, which delays RIPK2 ubiquitylation and NF-κB activation downstream of NOD engagement. Despite only delaying NF-κB activation on NOD stimulation, WEHI-345 prevents cytokine production in vitro and in vivo and ameliorates experimental autoimmune encephalomyelitis in mice. Our study highlights the importance of the kinase activity of RIPK2 for proper immune responses and demonstrates the therapeutic potential of inhibiting RIPK2 in NOD-driven inflammatory diseases.
Gov't Doc #: 25778803
URI: http://ahro.austin.org.au/austinjspui/handle/1/12688
DOI: 10.1038/ncomms7442
URL: https://pubmed.ncbi.nlm.nih.gov/25778803
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.